

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

### ANNOUNCEMENT PRINCIPAL FINANCIAL DATA AND INDICATORS OF FOSUN PHARMA FOR THE SIX MONTHS ENDED 30 JUNE 2012

On 27 August 2012, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("**Fosun Pharma**"), a subsidiary of Fosun International Limited (the "**Company**") and whose A shares are listed and traded on the Shanghai Stock Exchange (Stock Code: 600196), issued an announcement in relation to the extract of the 2012 interim report (the "**Announcement**").

The board of directors of the Company would like to draw the attention of its shareholders and the investment public to the following principal financial data and indicators of Fosun Pharma for the six months ended 30 June 2012 as set out in the Announcement:

#### Principal Financial Data and Indicators of Fosun Pharma

Unit: Yuan Currency: RMB

	As at the end of this reporting period	As at the end of last year	Increase/decrease as at the end of this reporting period as compared with the end of last year (%)
Total assets	22,322,154,015.70	22,290,818,173.51	0.14
Owners' equity (or shareholders' equity)	10,140,713,609.29	9,771,863,023.84	3.77
Equity per share attributable to shareholders of the listed company (yuan/share)	5.32	5.13	3.70
	Reporting period (January - June)	Same period last year	Increase/decrease of this reporting period as compared with the same period last year (%)
Operating profit	969,387,445.35	1,127,161,126.93	-14.00
Total profit	987,229,405.17	1,242,988,612.56	-20.58

Net profit attributable to shareholders of the listed company	701,766,957.49	866,699,742.64	-19.03
Net profit attributable to shareholders of the listed company net of non-recurring gain or loss	401,151,105.05	290,661,323.41	38.01
Basic earnings per share (yuan)	0.37	0.46	-19.03
Basic earnings per share net of non-recurring gain or loss (yuan)	0.21	0.15	40.00
Diluted earnings per share (yuan)	Not applicable	Not applicable	Not applicable
Weighted average return on equity (%)	7.00	9.71	Decreased by 2.78 percentage points
Net cash flow from operating activities	230,908,360.87	32,120,782.08	618.88
Net cash flow per share from operating activities (yuan)	0.12	0.02	500.00

Items and amounts of non-recurring gain or loss:

Unit: Yuan Currency: RMB

Items of non-recurring gain or loss	Amount
Gains or losses from disposal of non-current assets	231,468,172.76
Government grants (except for continuous government grants which are closely related to the normal operating business of the company and granted according to certain standardised amounts or quotas subject to national policy provision) included in gains or losses for the current period	13,000,344.07
Gains or losses from changes in fair values of trading financial assets and trading financial liabilities held by the company, and investment gains from disposal of trading financial assets and trading financial liabilities and financial assets available for sale, other than effective hedging activities associated with normal business operations of the company	218,222,165.62
Other non-operating income and expenses apart from the foregoing	902,359.57
Effect of income tax	-116,408,783.12
Effect of minority equity (after tax)	46,568,406.46
Total	300,615,852.44

Note: The full text of the 2012 interim report of Fosun Pharma and the Announcement will be published on the website of the Shanghai Stock Exchange (<http://www.sse.com.cn>).

By Order of the Board  
**Fosun International Limited**  
**Guo Guangchang**  
*Chairman*

Shanghai, the PRC, 27 August 2012

*As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Andrew Y. Yan, Mr. Zhang Huaqiao and Mr. David T. Zhang.*